Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (556)	7/16/2001 3:17:02 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 3557

Jim thanks, and folks were perhaps selling on the generality, not on the specifics of the rejection (not better vs existing therapy, side effects.) If a " me too" med is rejected, should not effect companies who have endevored to hit areas where good existing therapy (efficacy or side effectgs profile) is not in place, but knowing the market, distinction may not matter to a lot of the sellers. If this is a buying op, I unfortunately can't take advantage. WOuld like to add more MLNM and ABGX too at today's prices, but running up margin during this market climate is something I can't risk. My cash is unfortunately going to pay for an expensive, difficult diet and therapy for my son. Not reimbursable since they're "experimental" - kinda convenient fwhen there is no approved existing therapy for the indication. Oh well, on the plus side - I have the cash to apply there, lot of parents don't. And we live in a country where some therapy and information exists. Scott of the silver lining.